<DOC>
	<DOCNO>NCT00274963</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , bendamustine mitoxantrone , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study well give bendamustine together mitoxantrone work treat patient relapsed refractory B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Bendamustine Mitoxantrone Treating Patients With Relapsed Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate ( remission rate ) patient relapsed refractory B-cell chronic lymphocytic leukemia ( CLL ) treat bendamustine mitoxantrone hydrochloride . Secondary - Determine progression-free survival overall survival patient treat regimen . - Determine safety tolerability regimen patient . OUTLINE : This non-randomized , multicenter study . Patients receive bendamustine IV 1 hour days1-3 mitoxantrone hydrochloride IV 30 minute day 1 . Treatment repeat every 28 day least 2 course absence disease progression unacceptable toxicity . Patients respond disease ( i.e. , complete response partial response ) 2 course receive 2 additional course treatment total 4 course . After completion study treatment , patient follow periodically survival . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically immunophenotypically confirm diagnosis Bcell chronic lymphocytic leukemia ( CLL ) Relapsed refractory disease PATIENT CHARACTERISTICS : No know hypersensitivity study medication No uncontrolled infection No impair organ function PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>